Last updated: February 19, 2026
What is the current status of clinical trials for tecovirimat?
Tecovirimat, marketed as TPOXX® by SIGA Technologies, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of smallpox. It has also received Emergency Use Authorization (EUA) for monkeypox during the 2022 outbreak. Its development encompasses ongoing trials for other orthopoxvirus infections and biodefense-related indications.
Ongoing Clinical Trials
- NCT05534984: Phase II/III trial assessing safety and efficacy against monkeypox. Recruitment began in 2022, with completion expected by 2024.
- NCT04607186: Evaluates tecovirimat's efficacy in combination with immune globulin for severe monkeypox cases.
- NCT04786073: Investigates pharmacokinetics in children aged 2-17 years. Enrollment started in 2021.
Regulatory Status
- Approved in the U.S. (2018) for smallpox.
- Under EUA for monkeypox in the U.S. during the 2022 outbreak.
- Regulatory submissions underway or planned in Europe, Canada, and Australia for expanded indications.
What is the market landscape for tecovirimat?
Current Market
- Official Use: Limited to biodefense and select infectious disease emergencies.
- EUA Authorization: Declared for monkeypox in 2022, leading to increased utilization.
- Supply: Primarily supplied by SIGA, with potential for generic manufacturing pending patent and regulatory decisions.
Key Stakeholders
- SIGA Technologies: Holds patent rights and marketing authorization.
- Government agencies: U.S. CDC, BARDA, and international health authorities manage stockpiles and emergency use approvals.
- Competitors: No direct FDA-approved competitors for smallpox; other antivirals like brincidofovir are investigational.
Market Drivers
- Growing threat of bioterrorism involving orthopoxviruses.
- Outbreaks of monkeypox prompting emergency use and stockpiling.
- Genomic stability of orthopoxviruses reducing resistance development.
Market Barriers
- Limited approval scope restricts commercial sales.
- High production costs.
- Patent protections delaying generic entry.
What are projections for the future market of tecovirimat?
Market Size Forecast
| Year |
Estimated Market Value (USD) |
Notes |
| 2022 |
120 million |
Surge due to monkeypox outbreak and EUA authorization |
| 2023 |
180 million |
Extended use in monkeypox and potential new indications |
| 2025 |
300 million |
Expected broader adoption, possible EU approval for additional indications |
| 2030 |
500 million to 1 billion |
Contingent on global regulatory approvals and outbreak frequency |
Factors Influencing Growth
- Regulatory approvals: Expansion into Europe, Asia, and Australia could significantly increase sales.
- Indication expansion: Clinical success in other orthopoxvirus diseases or bioterrorism-related infections.
- Manufacturing scale-up: Gaining approval for generic manufacturing would moderate prices and improve access.
- Public health policies: Investment in biodefense preparedness influences procurement volume.
Potential Market Risks
- Emergence of resistance mutations.
- Changes in public health policies affecting stockpiling priorities.
- Competition from other antiviral candidates advancing through clinical development.
Key Takeaways
- Tecovirimat is FDA-approved for smallpox, with ongoing trials for monkeypox.
- The drug's market surged in 2022 due to the monkeypox outbreak and EUA issuance.
- The current market is driven by stockpiling and emergency use, with future growth reliant on expanded approvals and indications.
- Projected valuation could reach USD 1 billion by 2030, contingent on regulatory, clinical, and geopolitical factors.
- Market barriers include high manufacturing costs and patent protections, while risks include resistance development and shifting policy landscapes.
FAQs
1. When was tecovirimat first approved for smallpox?
In 2018 by the FDA under the brand name TPOXX®.
2. Is tecovirimat approved for monkeypox?
No, it has Emergency Use Authorization in the U.S. since 2022.
3. Are there any generic versions of tecovirimat?
Not currently; patent protections and regulatory exclusivity limit generic entry.
4. What other diseases could tecovirimat potentially treat?
Research is ongoing for its use against other orthopoxviruses and bioterrorism-related infections.
5. How does tecovirimat compare to other antiviral agents?
It targets the orthopoxvirus-specific p37 protein, offering a targeted mechanism less prone to resistance compared to broader-spectrum antivirals.
References
[1] U.S. Food and Drug Administration. (2018). FDA approves first drug with demonstrated or proposed activity against smallpox. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-demonstrated-or-proposed-activity-against-smallpox
[2] ClinicalTrials.gov. (2022). Tecovirimat trials for monkeypox. https://clinicaltrials.gov/
[3] SIGA Technologies. (2023). TPOXX Product Data. https://siga.com/products/tpoxx/
[4] World Health Organization. (2022). Monkeypox: update on outbreak. https://www.who.int/news/item/23-08-2022
[5] MarketsandMarkets. (2023). Antiviral drugs market analysis. https://www.marketsandmarkets.com
